Mirae Asset Global Investments
RLMD icon

Mirae Asset Global Investments’s Relmada Therapeutics RLMD Stock Holding History

Mirae Asset Global Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-270,396
Closed -$1.12M – 2616
2023
Q4 		$1.12M Buy
270,396
+11,387
+4% +$33.7K ﹤0.01% 1559
2023
Q3 		$777K Sell
259,009
-79,936
-24% -$237K ﹤0.01% 1666
2023
Q2 		$834K Buy
338,945
+49,999
+17% +$138K ﹤0.01% 1676
2023
Q1 		$653K Buy
288,946
+9,531
+3% +$32.9K ﹤0.01% 1798
2022
Q4 		$975K Buy
279,415
+207,382
+288% +$1.82M ﹤0.01% 1510
2022
Q3 		$2.67M Buy
72,033
+28,589
+66% +$792K 0.01% 1025
2022
Q2 		$519K Buy
+43,444
New +$948K ﹤0.01% 1732

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mirae Asset Global Investments's RLMD Position: Q1 2024 in Review

Mirae Asset Global Investments sold out of Relmada Therapeutics (RLMD) in Q1 2024, closing a stake of 270,396 shares — an estimated $1.12M sold.

Mirae Asset Global Investments first reported a position in RLMD in Q2 2022 and held it in 7 quarters. The position peaked at $2.67M in Q3 2022. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

  • Mirae Asset Global Investments reported no remaining Relmada Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 270,396 Relmada Therapeutics shares in Q1 2024, an estimated $1.12M.
  • Mirae Asset Global Investments first reported a position in Relmada Therapeutics in Q2 2022 and held it in 7 quarters.
  • Mirae Asset Global Investments's Relmada Therapeutics position peaked at $2.67M in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on Mirae Asset Global Investments's 13F filing for Q1 2024, filed 1 May 2024.